Value Of ERCC1 And TS For Chemotherapy Effectiveness And Prognosis In Human Metastatic Colon Cancer

Objective:Explore the relationship of ERCC1 and TS with chemotherapy effectiveness and prognosis in human metastatic colon cancerMethods:82 cases of metastatic colon cancer patients received FOLFOX as first-line therapy, After failure or appeared the chemotherapy dosage restrictive toxicity, received FOLFIRI in second-line therapy.Object two chemotherapies effectiveness, Progression-free suivival(PFS) and Overall suivival(OS). The expression of ERCC1 and TS were examined in tumor samples by the immunohistochemical method ((Maxvisiontm).All patients were followed up for 2 years.Results:1. In first-line Chemotherapy 82 cases of patients,the effectiveness was 61.9% in ERCC1 negative group,and 30.0% in ERCC1 positive group respectively,there were significant difference between the two groups(P<0.05);the effectiveness was 60.0% in TS negative group,and 36.2% in TS positive group respectively,there were significant difference between the two groups(p<0.05). The effectiveness was 65.0%(13/20)in both of two negative group,59.1%(13/22)in ERCC1 negative and TS positive group,53.3%(8/15)in ERCC1 positive and TS negative group,and 16.0% (4/25)in both of two positive group respectively,both of two positive group significant lower than other groups(p<0.05),but there were no significant difference between other groups(p>0.05).In second-line Chemotherapy, the effectiveness was 38.1% in ERCC1 negative group, and 37.5% in ERCC1 positive group respectively,there were no significant difference between the two groups(p>0.05);the effectiveness was 60.0% in TS negative group, and 21.3% in TS positive group respectively,there were significant difference between the two groups(p<0.05). The effectiveness was 60.0%(12/20)in both of two negative group,18.2%(4/22)in ERCC1 negative and TS positive group,60.0%(9/15)in ERCC1 positive and TS negative group,and 24.0%(6/25)in both of two positive group respectively, statistical analysis showed that the effectiveness was significant higher in TS negative groups(p<0.05),but the expression of ERCC1 was unrelated with the effectiveness (p>0.05).2. Followed up for 2 years, In first-line Chemotherapy,the median PFS was 4.6 months in ERCC1 positive group,and 6.8 months in ERCC1 negative group respectively(p<0.05), Kaplan-Meier Survival curves showed that the ERCC1 negative group superior than positive group and the difference was significant (p<0.001); the median PFS was 4.6months in TS positive group,and 6.7months in TS negative group respectively, Kaplan-Meier Survival curves showed that the TS negative group superior than positive group and the difference was significant (p<0.001). The median PFS was 7.5months in both of two negative group,6.4months in ERCC1 negative and TS positive group,6.3months in ERCC1 positive and TS negative group,and 4months in both of two positive group respectively, Kaplan-Meier Survival curves showed that both of two negative group superior than other groups,the PFS of both of two positive group were significant shorter than other groups(p<0.001),there were no significant difference between both of two negative groups and one of them negative groups (p>0.05).In second-line Chemotherapy, the median PFS was 1.5 months in ERCC1 positive group, and 1.7 months in ERCC1 negative group respectively,there were no significant difference(p=0.102);the median PFS was 1.4months in TS positive group,and 2.0months in TS negative group respectively, Kaplan-Meier Survival curves showed that the TS negative group superior than positive group and the difference was significant (p<0.001). The median PFS was 2.0months in both of two negative group,1.3months in ERCC1 negative and TS positive group,2.0months in ERCC1 positive and TS negative group,and 1.4months in both of two positive group respectively, Kaplan-Meier Survival curves showed that both of two negative group similar to ERCC1 positive and TS negative group,both of two positive group similar to ERCC1 negative and TS positive group,the PFS of TS positive groups were significant shorter than TS negative groups(p<0.05).3. In 82 cases of patients,the median OS was 10.5months in ERCC1 positive group,and 14months in ERCC1 negative group respectively, Kaplan-Meier Survival curves showed that the ERCC1 negative group superior than positive group and the difference was significant(p<0.05); the median OS was 11months in TS positive group,and 15months in TS negative group respectively, Kaplan-Meier Survival curves showed that the TS negative group superior than positive group and the difference was significant (p=0.001). The median OS was 15months in both of two negative group,13months in ERCC1 negative and TS positive group,13.5months in ERCC1 positive and TS negative group,and 10months in both of two positive group respectively,Kaplan-Meier Survival curves showed that both of two negative group similar to one of them negative group,the OS of both of two positive group were significant shorter than other groups(p<0.05),there were no significant difference between both of two negative group and one of them negative groups(p>0.05).4.COX multi-factor regression analysis showed that both the expression of ERCC1 and TS were independent prognostic factors in human metastatic colon cancer.Conclusion:1.In metastatic colon cancer patients, both of ERCC1 and TS negative or one of them nengative can benefit from FOLFOX,and TS negative can benefit from FOLFRI..The ERCC1 was unrelated with the effectiveness and prognosis of FOLFIRI.2.The expression of ERCC1 and TS can serve as factors for effectiveness and prognosis in metastatic colon cancer.